VRTX
Vertex Pharmaceuticals Inc
NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY
$429.85
+1.40% today
Updated 2026-05-01
Market cap
$108.71B
P/E ratio
27.93
P/S ratio
9.06x
EPS (TTM)
$15.30
Dividend yield
—
52W range
$363 – $508
Volume
1.3M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A8.0
Quality
A9.0
Profitability
A+6.7
Valuation
B3/9
Piotroski F-Score
Weak
3.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$548.39
+27.58%
12-Month target
$450.07
+4.70%
Intrinsic (DCF)
$973.13
Margin of safety
+56.44%
5 Strong Buy22 Buy4 Hold1 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.62 — safe zone
+ Profit margin 32.90% — above average
+ ROE 22.50% — strong efficiency
+ Free cash flow $348.60M — positive
+ 56.44% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $8.93B | $9.87B | $11.02B | $12.07B | $12.00B | $13.3B |
| Net income | $3.32B | $3.62B | $-535.60M | $3.95B | $1.19B | — |
| EPS | — | — | — | — | $15.30 | $19.39 |
| Free cash flow | $3.93B | $3.28B | $-790.30M | $3.19B | $348.60M | — |
| Profit margin | 37.20% | 36.68% | -4.86% | 32.74% | 32.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | UPADHYAY, SUKETU | Buy | 81 | $442.50 |
| 2026-04-15 | SACHS, BRUCE I | Buy | 107 | $442.50 |
| 2026-04-15 | GARBER, ALAN M | Buy | 34 | $442.50 |
Peer comparison
Smart narrative
Vertex Pharmaceuticals Inc trades at $429.85. representing a P/E of 27.93x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.62, it sits in the safe zone. TTM revenue stands at $12.00B. with profit margins at 32.90%. Our DCF model estimates intrinsic value at $973.13.
Frequently asked questions
What is Vertex Pharmaceuticals Inc's stock price?
Vertex Pharmaceuticals Inc (VRTX) trades at $429.85.
Is Vertex Pharmaceuticals Inc overvalued?
Smart Value Score 66/100 (Grade B, Buy). DCF value $973.13.
What is the price target of Vertex Pharmaceuticals Inc (VRTX)?
The analyst target price is $548.39, representing +27.6% upside from the current price of $429.85.
What is the intrinsic value of Vertex Pharmaceuticals Inc (VRTX)?
Based on our DCF model, intrinsic value is $973.13, a +56.4% margin of safety versus $429.85.
What is Vertex Pharmaceuticals Inc's revenue?
TTM revenue is $12.00B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.62 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.06x
ROE22.50%
Beta0.37
50D MA$454.43
200D MA$436.43
Shares out0.25B
Float0.25B
Short ratio—
Avg volume1.3M
Performance
1 week-1.45%
1 month-3.37%
3 months-8.95%
YTD-6.49%
1 year—
3 years—
5 years—